GATEWAY BIOTECHNOLOGY, INC — Department of Defense SBIR: MEDICAL RESEARCH AND DEVELOPMENT CONTRACT DHA SBIR PH II, PROPOSAL NO. H2S-0048, TITLED: "
GATEWAY BIOTECHNOLOGY, INC — SBIR award from Department of Defense.
Summary
Gateway Biotechnology received nearly $1.95 million from the Defense Health Agency for an SBIR Phase II project to develop a new drug called GW-TT2 for treating tinnitus. The award supports medical research and development of this pharmaceutical product.
- Amount
- $1,949,999
- Agency
- Department of Defense · Defense Health Agency
- Program / Phase
- SBIR
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- OH
- Period
- 2023-09-18 → 2027-08-23
Technology domains
Description
MEDICAL RESEARCH AND DEVELOPMENT CONTRACT DHA SBIR PH II, PROPOSAL NO. H2S-0048, TITLED: "GW-TT2, A NEW DRUG PRODUCT FOR TINNITUS"